Competitiveness / Health Care
This section feature research, opinion and progress reports on how the Czech Republic compares to other EU countries economically. It includes analysis of international rankings such as the WEF and World Bank.
Show subcategories ▾
Spotlight issue
Pfizer and Biontech to potentially supply the EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval
The vaccine supply for the EU would be produced by BioNTech’s manufacturing sites in Germany and Pfizer’s manufacturing site in Belgium
Pfizer and BioNTech are on track to seek regulatory review of BNT162b2 as early as October 2020 and, if regulatory authorization or approval is obtained, currently plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021
View more
Twitter
Linkedin
Facebook
Google+
Will COVID-19 vaccines ‘save the world’?
Innovators are sprinting to develop inoculations against the novel coronavirus. Here, we summarize the latest information on research timelines and the potential impact of a vaccine on the pandemic—and society.
View more
How Pfizer and BioNTech are moving with safety and speed to develop a potential COVID-19 vaccine
Since Pfizer and our collaboration partner, BioNTech, begun our mission to develop a COVID-19 vaccine, safety has been our guiding principle every step of the way.
At the same time, given the urgency of the global pandemic, we continue to move at record-breaking speed. We recently started the phase 2/3 safety and efficacy trial for our lead vaccine candidate, approximately three months after we started the phase 1/2 safety and immunogenicity trials in Germany and the United States for our four initial vaccine candidates. Progressing from the start of clinical testing for a vaccine candidate in small numbers of trial participants to a large-scale efficacy trial is a process that can usually take years, sometimes even a decade.
View more
